Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10216/143539Registo completo
| Campo DC | Valor | Idioma |
|---|---|---|
| dc.creator | Fonseca, C | |
| dc.creator | Brito, D | |
| dc.creator | Branco, P | |
| dc.creator | Frazão, JM | |
| dc.creator | Silva-Cardoso, J | |
| dc.creator | Bettencourt, P | |
| dc.date.accessioned | 2022-08-29T14:35:36Z | - |
| dc.date.available | 2022-08-29T14:35:36Z | - |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 0870-2551 | |
| dc.identifier.uri | https://hdl.handle.net/10216/143539 | - |
| dc.description.abstract | Introduction and Objectives: Renin-angiotensin-aldosterone system inhibitors (RAASi) are the cornerstone of treatment of heart failure with reduced ejection fraction (HFrEF). RAASi optimization in real-life care is challenged by hyperkalemia, a potentially fatal adverse event, which can necessitate downtitration or discontinuation of RAASi and negatively impact survival in HFrEF. The literature on this problem is sparse. We performed a systematic review of studies on HFrEF to investigate the prevalence, incidence, and risk factors of hyperkalemia, RAASi prescription rates, frequency of RAASi downtitration or discontinuation due to hyperkalemia, and the potential negative effect of the latter on prognosis. Methods: We conducted a MEDLINE (PubMed) search including observational and interventional studies published between January 1987 and May 2018. Results: A total of 30 observational and 18 interventional studies were included in the review. The incidence of hyperkalemia reported was between 0% and 63% in observational studies and was between 0% and 30% in clinical trials. Risk factors for hyperkalemia included RAASi prescription, older age, diabetes, and chronic kidney disease. In real-life studies, RAASi were downtitrated or discontinued in 3-22% of HFrEF patients; hyperkalemia was the reported cause in 5% of cases. No reports were found on the impact on prognosis of RAASi downtitration or discontinuation due to hyperkalemia. Conclusions: Hyperkalemia and RAASi downtitration or discontinuation are frequent, particularly in real-life HFrEF studies. Further research is needed to clarify the role of RAASi downtitration or discontinuation due to hyperkalemia and to assess its long-term prognostic impact in HFrEF patients. | |
| dc.description.sponsorship | This work was supported by OM Pharma (Amadora, Portugal) for the payment of medical writing support. OM Pharma had no role in the study design, or in the collection, analysis and interpretation of data, or in the writing of the manuscript, or the decision to submit the manuscript for publication. The views expressed in the manuscript are those of the authors and not necessarily those of OM Pharma. | |
| dc.language.iso | eng | |
| dc.publisher | Elsevier | |
| dc.relation.ispartof | Revista Portuguesa de Cardiologia, vol.39(9), p. 517-541 | |
| dc.rights | openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Clinical decision-making | |
| dc.subject | Clinical outcomes | |
| dc.subject | Drug therapy | |
| dc.subject | Heart failure | |
| dc.subject | Hyperkalemia | |
| dc.subject | Renin-angiotensin-aldosterone system inhibitors | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Angiotensin Receptor Antagonists | |
| dc.subject.mesh | Angiotensin-Converting Enzyme Inhibitors | |
| dc.subject.mesh | Heart Failure / drug therapy | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Hyperkalemia | |
| dc.subject.mesh | Renin-Angiotensin System / drug effects | |
| dc.subject.mesh | Stroke Volume | |
| dc.title | Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review | |
| dc.type | Artigo em Revista Científica Internacional | |
| dc.contributor.uporto | Instituto de Investigação e Inovação em Saúde | |
| dc.identifier.doi | 10.1016/j.repc.2020.03.015 | |
| dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S0870255120303474?via%3Dihub | |
| Aparece nas coleções: | I3S - Artigo em Revista Científica Internacional | |
Ficheiros deste registo:
| Ficheiro | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| 10.1016-j.repc.2020.03.015.pdf | 1.59 MB | Adobe PDF | ![]() Ver/Abrir |
Este registo está protegido por Licença Creative Commons
